Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2009, Article ID 547582, 4 pages
http://dx.doi.org/10.1155/2009/547582
Clinical Study

Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

1Department of Hematology, Singapore General Hospital, Singapore 169608
2Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore 169547
3CLL Unit, Royal Marsden Hospital, London SW3 6JJ, UK

Received 8 September 2008; Accepted 15 December 2008

Academic Editor: Luen Bik To

Copyright © 2009 William Y. K. Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. L. Kwong, K. F. Wong, L. C. Chan et al., “The spectrum of chronic lymphoproliferative disorders in Chinese people. An analysis of 64 cases,” Cancer, vol. 74, no. 1, pp. 174–181, 1994. View at Publisher · View at Google Scholar
  2. S. Demko, J. Summers, P. Keegan, and R. Pazdur, “FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia,” The Oncologist, vol. 13, no. 2, pp. 167–174, 2008. View at Publisher · View at Google Scholar
  3. M. J. Keating, I. Flinn, V. Jain et al., “Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study,” Blood, vol. 99, no. 10, pp. 3554–3561, 2002. View at Publisher · View at Google Scholar
  4. T. Elter, P. Borchmann, H. Schulz et al., “Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7024–7031, 2005. View at Publisher · View at Google Scholar
  5. M. Montillo, A. M. Cafro, A. Tedeschi et al., “Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine,” Haematologica, vol. 87, no. 7, pp. 695–700, 2002. View at Google Scholar
  6. S. Stilgenbauer, A. Krober, D. Winkler et al., “Efficacy of subcutaneous alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL study group,” Annals of Oncology, vol. 16, abstract 41, 2005. View at Google Scholar
  7. M. A. Boogaerts, A. Van Hoof, D. Catovsky et al., “Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 19, no. 22, pp. 4252–4258, 2001. View at Google Scholar
  8. B. D. Cheson, J. M. Bennett, M. Grever et al., “National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment,” Blood, vol. 87, no. 12, pp. 4990–4997, 1996. View at Google Scholar
  9. J. Aubin, F. Davi, F. Nguyen-Salomon et al., “Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies,” Leukemia, vol. 9, no. 3, pp. 471–479, 1995. View at Google Scholar
  10. M. L. Sánchez, J. Almeida, B. Vidriales et al., “Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation,” Leukemia, vol. 16, no. 8, pp. 1460–1469, 2002. View at Publisher · View at Google Scholar
  11. H. A. Sayala, P. Moreton, R. A. Jones et al., “Final report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group),” Blood, vol. 108, no. 11, abstract 34, 2006. View at Google Scholar